In Brief: AngioDynamics
This article was originally published in The Gray Sheet
AngioDynamics: Wholly-owned E-Z-EM subsidiary gains 510(k) clearance for its Transjugular Access Set catheter system designed for minimally invasive liver operations such as TIPS (transjugular intrahepatic portal shunt) procedures. The system consists of a series of coaxial catheters and needles "which will cause less damage to other liver structures such as the bile duct as the physician establishes a pathway between the hepatic and portal veins," AngioDynamics President Eamonn Hobbs says in a June 17 release. The firm also is in the process of designing the AngioStent for malignant bile duct obstructions; the stent already is being sold outside the U.S. for cardiovascular indications...
You may also be interested in...
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.